

# Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization

## Agenda

23 - 25 October 2018

CICG, Geneva, Switzerland

Draft 25 September 2018

**Tuesday, 23 October 2018**

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
09:15	<b>Welcome – introduction of participants</b> A. CRAVIOTO. Chair of SAGE.		15 min.
09:30	<b>Report from Director, IVB and Regional Updates– Session 1</b>  Global report including key updates and challenges from Regions. M FRIEDE. WHO. 30 min. Discussion 1 h.  <b>WHO Focal point</b> M FRIEDE, REGIONAL ADVISERS <b>SAGE Focal Point</b> A CRAVIOTO	<b>FOR INFORMATION;</b>	1 h 30 min.
<b>11:00</b>	<b>Coffee/tea break</b>	<b>Break</b>	<b>30 min.</b>
11:30	<b>Report from Gavi, the Vaccine Alliance– Session 2</b>  Report from Gavi, the Vaccine Alliance. S. BERKLEY. Gavi, the Vaccine Alliance. 15 min. Discussion 15 min.  <b>WHO Focal point</b> L KAMARA <b>SAGE Focal Point</b> A CRAVIOTO	<b>FOR INFORMATION</b>	30 min.
12.00	<b>Reports from other Advisory Committees on Immunization– Session 3</b>  Report from Global Advisory Committee on Vaccine Safety (GACVS). R PLESS. GACVS Chair. 10 min. Discussion 10 min.  <b>WHO Focal point</b> P ZUBER <b>SAGE Focal Point</b> K JOHANSEN	<b>FOR INFORMATION</b>  Report from June 2018 meeting	1 h 30 min.

	Report from Immunization and Vaccines related Implementation Research Advisory Committee (IVIR-AC). R. BREIMAN. 10 min. Discussion 10 min.	Report from September 2018 meeting
	<b>WHO Focal point</b> R HUTUBESSY <b>SAGE Focal Point</b> C WIYSONGE	
<b>12:40</b>	<b>Lunch</b>	<b>Break</b>
		<b>1 h 05 min.</b>
13:45	<b>Cont. Reports from other Advisory Committees on Immunization– Session 3</b>	
	Report from Immunization Practice Advisory Committee (IPAC). C MORGAN. Chair of IPAC. 10 min. Discussion 10 min.	Report from July meeting
	<b>WHO Focal point</b> AL KAHN <b>SAGE Focal Point</b> I JANI	
	Report from Product Development for Vaccines Advisory Committee (PDVAC). D KASLOW. PDVAC Chair. 20 min. Discussion 10 min.	<ul style="list-style-type: none"><li>• Report from June meeting to highlight progress on product development of selected vaccines and monoclonal antibody candidates for PDVAC prioritized pathogens</li><li>• Brief discussion on the role of controlled human infection models in licensure and policy decisions</li></ul>
	<b>WHO Focal point</b> B GIERSSING <b>SAGE Focal Point</b> A CRAVIOTO	
14:35	<b>Global Vaccine Action Plan (GVAP)– Session 4</b>	<b>2 h 15 min.</b>
	Update from the GVAP Secretariat. C STEFFEN. WHO. 5 min	<b>FOR DECISION</b> SAGE is asked to produce an independent annual report on progress with the Decade of Vaccines Global Vaccine Action Plan.
	Summary of GVAP implementation progress review and recommendations for additional efforts. N MACDONALD, Chair of SAGE Decade of Vaccines Working Group. 25 min. Discussion 1 h.	Specially, SAGE will be asked to: <ul style="list-style-type: none"><li>• Review the DoV WG “Assessment report on DoV progress 2018 ” based on the “GVAP Secretariat report</li></ul>

		<p>2018”, the regional reports on the implementation of regional vaccine action plans, and some independent stakeholder submissions. This year’s review encompasses in addition a focus on the GVAP research and development indicators.</p> <ul style="list-style-type: none"> <li>Identify successes, challenges and areas where additional efforts or corrective actions by countries, regions, partners, donor agencies or other parties, are needed.</li> </ul>	
<b>16:05</b>	<b>Coffee/tea break</b>	<b>Break</b>	<b>30 min.</b>
16:35	<b>Cont. Global Vaccine Action Plan (GVAP)– Session 4</b>		
	<p>Process to develop a post-2020 Global Immunization Strategy 2021-2030. P LYDON. WHO. 15 min. Discussion: 30 min.</p> <p><b>WHO Focal point</b> C STEFFEN <b>SAGE Focal Point</b> N MACDONALD</p>		
	<p><b>FOR DISCUSSION</b></p> <ul style="list-style-type: none"> <li>SAGE will also be presented with a high-level perspective on the development of a post-2020 immunization strategy</li> <li>Discuss the articulation with the current GVAP reporting and monitoring process.</li> </ul>		
17:20	<b>Report of activities from international immunization partners– Session 5</b>		
	<p>Introduction M GURAIIB. WHO. 10 min.</p> <p>PREVENT initiative - Pregnant Women &amp; Vaccines Against Emerging Epidemic Threats: Ethics Guidance for Preparedness, Research, &amp; Response R KARRON. 15 min. Discussion 15 min.</p> <p><b>WHO Focal point</b> M PERUT AND P LAMBACH <b>SAGE Focal Point</b> A CRAVIOTO</p>		
	<p><b>FOR INFORMATION</b></p> <ul style="list-style-type: none"> <li>Global Guidance For Managing Ethical Issues In Infectious Disease Outbreaks</li> </ul> <p><b>FOR INFORMATION</b></p> <p>Roadmap for the ethically responsible, socially just, and respectful inclusion of the interests of pregnant women in the development and deployment of vaccines against emerging pathogens. A draft guidance to support that pregnant women and their offspring</p> <ul style="list-style-type: none"> <li>could benefit from advances in vaccine technologies</li> <li>are not excluded from participating in vaccine studies,</li> <li>could benefit from vaccines to protect them against emerging and re-emerging pathogenic threats.</li> </ul>		40 min.
<b>18:00</b>	<b>End of Day 1, Cocktail</b>		

**Wednesday, 24 October 2018**

<b>Time</b>	<b>Session</b>	<b>Purpose of session, target outcomes and questions for SAGE</b>	<b>Duration</b>
09:15	<b>Polio– Session 6</b>  Overview of the Global Polio Eradication Initiative. M ZAFFRAN. WHO. 25 min.  Independent evaluation of the eradication program in Afghanistan, Pakistan and Nigeria by the “Independent Monitoring Board”. S L DONALDSON 20 min.  Report from SAGE Polio Working Group. P FIGUEROA. SAGE Polio Working Group Member. 20 min.  Discussion: 55 minutes  <b>WHO Focal Point</b> O MACH <b>SAGE Focal Point</b> I JANI	<b>FOR INFORMATION / DISCUSSION</b>  Current status of the polio eradication program; Independent evaluation of the progress; Appraisal of options regarding certification of polio eradication.	2 h.
10:45	<b>Coffee/tea break</b>	<b>Break</b>	<b>30 min.</b>
11:15	<b>Cont. Polio– Session 6</b>  Discussion		
11:45	<b>Measles and Rubella– Session 7</b> Session introduction. N TURNER. SAGE member. 5 min.  Global update. A DABBAGH. WHO. 10 min. Discussion 15 min.  Feasibility of MR eradication. B MOSS. Measles and Rubella Working Group member. 15 min. Discussion 20 min.	<b>FOR INFORMATION</b> • Global and regional update  <b>FOR DISCUSSION</b> • Presentation of the plan to address the feasibility and financial resource requirements for measles and rubella eradication. • Guidance from SAGE on the approach to addressing the feasibility question	2 h 15 min.
12:50	<b>Lunch</b>	<b>Break</b>	<b>1 h 10 min.</b>
14.00	<b>Cont. Measles and Rubella– Session 7</b> Co-administration of the YF vaccine with measles containing vaccines. J HARRIS. Centers for Disease Control and Prevention. 15 min.	<b>FOR DECISION</b> • Presentation of studies on potential interference between	

<p>Discussion 15 min.</p> <p>Country classifications and guidance to increasing population immunity . S REEF. Measles and Rubella Working Group member. 20 min. Discussion 20 min.</p> <p><b>WHO Focal Point</b> A DABBAGH <b>SAGE Focal Point</b> N TURNER</p>	<p>MCVs and YF vaccine including the findings of the most recent RCT in Argentina.</p> <p><b>FOR DECISION</b></p> <ul style="list-style-type: none"> <li>• A roadmap for countries towards closing immunity gaps and achieving elimination.</li> <li>• Recommendations for key priorities for countries according to their level of control.</li> </ul>
<p>15.10 <b>Human papilloma virus (HPV) vaccines– Session 8</b></p> <p>Session introduction and key questions. R AGGARWAL. SAGE Member. 5 min.</p> <p>Update on HPV vaccine introduction and programmatic perspective. I OGBUANU. WHO. 15 min.</p> <p>Overview of evidence regarding HPV immunization on different disease outcomes A. POLLARD. SAGE member. 15 min.</p>	<p><b>FOR DECISION</b> 2 h.</p> <p>Present SAGE with updated evidence on HPV-related burden, HPV vaccines, impact of HPV immunization programmes, and modelling of impact of HPV immunization schedules and strategies.</p> <p>SAGE is requested to consider the following questions:</p> <ul style="list-style-type: none"> <li>• What are the potential effect and cost effectiveness of various vaccination strategies towards the achievement of cervical cancer elimination?</li> <li>• What is the potential contribution of HPV vaccination towards cervical cancer elimination?</li> <li>• What are the interim goals that can be achieved through immunization as part of the efforts towards cancer elimination.</li> <li>• What are the indicators to monitor the accomplishment of these interim goals?</li> <li>• What is additional research related to vaccines and immunization needed to attain these goals and outline potential innovations that may ease the achievement of these goals?</li> </ul>
<p><b>15:45 Coffee/tea break</b></p>	<p><b>Break 30 min.</b></p>
<p>16:15 <b>Cont. Human papilloma virus (HPV) vaccines– Session 8</b></p> <p>Forecast impact of different immunization strategies and screening scenarios towards cervical cancer elimination. M BRISSON. Laval University. 20 min.</p> <p>Conclusions and proposed recommendations by SAGE Working Group. R AGGARWAL. SAGE Member. 10 min. Discussion: 50 min</p>	

**WHO Focal point**  
AM HENAO RESTREPO, T GOODMAN  
**SAGE Focal Point**  
R AGGARWAL

**17:40 End of Day 2**

**Thursday, 25 October 2018**

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
08:45	<p><b>Ebola and other unlicensed vaccines for emergency use - Session 9</b></p> <p>Session introduction and key questions. F WERE. SAGE Member and Co-Chair of the Working Group. 5 min.</p> <p>Overview of Ebola epidemiology. D HEYMANN. LSHTM and Chatham House. 15 min.</p> <p>Update on candidate Ebola vaccines: available data on immunogenicity, efficacy and safety, timelines for licensure and Expanded Access/Compassionate Use experience. AM HENAO-RESTREPO. WHO. 15 min.</p> <p>Benefits and risk analysis of vaccination of pregnant women with rVSV-ZEBOV as part of Expanded Access/ Compassionate Use during Ebola outbreaks. C JARVIS and J EDMUNDS, LSHTM. 15 min.</p> <p>Observed and forecasted impact of different Ebola candidate immunization strategies and targeted populations. A CAMACHO. EPICENTRE. 15 min.</p> <p>Questions for clarification. 15 min.</p> <p>Proposed recommendations by SAGE Working Group. H REES. Working Group Member. 15 min.</p> <p>Discussion 40 min.</p> <p><b>WHO Focal point</b> AM HENAO RESTREPO <b>SAGE Focal Point</b> F WERE</p>	<p><b>FOR DECISION</b></p> <p>SAGE is asked to provide recommendations on the use of such unlicensed vaccines and the anticipated impact of various vaccination strategies.</p> <p>SAGE is requested to consider the following questions:</p> <ul style="list-style-type: none"> <li>Is the current evidence sufficient for SAGE to adjust current recommendations regarding the use of Ebola vaccines in case of another Ebola outbreak? If yes, which recommendations can be proposed? And, what key data are missing?</li> <li>What are the conclusions from the benefits and risk analysis of vaccination of pregnant women with rVSV-ZEBOV as part of Expanded Access/ Compassionate Use during Ebola outbreaks?</li> <li>Are there remaining challenges that may prevent access to Ebola vaccines in future outbreaks, and, if yes, can SAGE make recommendations on how these might be addressed?</li> </ul>	2 h 15 min.
<b>11:00</b>	<b>Coffee/tea break</b>	<b>Break</b>	<b>30 min.</b>
11:30	<p><b>Lessons learned from Diphtheria outbreaks: opportunities for early warning and preventive action- Session 10</b></p>	<p><b>FOR INFORMATION AND DISCUSSION</b></p> <p>Purpose of this session is to review and discuss programmatic data available at HQ and how it can be strengthened or</p>	1 h 45 min.

Introduction to session.  
F QADRI. SAGE Member, 5 min.

Case study – Diphtheria Outbreak in Cox Bazaar.  
S BAHL. WHO., SEARO, Regional Office. 10 min.

Global Opportunities and Gaps in Preventing Diphtheria Outbreaks.  
M GACIC-DOBO. WHO. 20 min.

Country level risk assessment tool for Diphtheria: an example of possible approaches to guide country level actions (work in progress).  
S HADLER. Task Force Global Health. 15 min.

Vaccine decision information systems (work in progress)  
W. PANHUIS. University of Pittsburgh. 10 min.

Discussion and proposed next steps. 45 min.

**WHO Focal point**  
S DESAI AND AM HENAO RESTREPO  
**SAGE Focal Point**  
F QADRI

analyzed differently to anticipate or prevent outbreaks of VPDs. The diphtheria outbreak in Cox's Bazaar will be used as a case study.

In addition, SAGE will be presented with two approaches being explored. A pragmatic approach (excel-based) using routinely available data at the country level to predict the prospective risk of diphtheria. The second is an approach using subnational data for risk analysis to strengthen vaccination strategies.

SAGE is requested to note these ongoing efforts and to suggest additional actions for this area of work, including but not limited to other data elements to consider and other analytical approaches that should be explored.

**13:15 Closing**

**13:30 End of meeting**